Aquinnah Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 7
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $4.15M
Latest Deal Amount
  • Investors
  • 6

Aquinnah General Information

Description

Developer of neurodegenerative stress granules intended for the treatment of critical diseases. The company leverages brain pathology to design innovative therapies to slow the progression of amyotrophic lateral sclerosis and other neuron diseases, enabling physicians and the medical community to combat sclerosis, Alzheimer's and other neurodegenerative conditions.

Contact Information

Website
www.aquinnahpharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • Lab Central
  • 610 Main Street
  • Cambridge, MA 02139
  • United States
+1 (617) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Aquinnah Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 01-May-2020 $4.15M 0000 Completed Generating Revenue
3. Early Stage VC 25-Apr-2017 0000 0000 Completed Generating Revenue
2. Corporate 21-Dec-2015 $5M $5M Completed Startup
1. Grant 23-Nov-2015 $680K Completed Startup
To view Aquinnah’s complete valuation and funding history, request access »

Aquinnah Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of neurodegenerative stress granules intended for the treatment of critical diseases. The company leverages br
Drug Discovery
Cambridge, MA
7 As of 2022
0000
0000000000 0000

00000000

t enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo cons
0000 000000000
San Diego, CA
000 As of 0000
00000
0000000 0000 00000

00000000

or sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
0000 000000000
Kalamazoo, MI
00 As of 0000
0000
0000000000 0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aquinnah Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biosplice Therapeutics Private Equity-Backed San Diego, CA 000 00000 0000000 0000 00000
000000000 00000000 Venture Capital-Backed Kalamazoo, MI 00 0000 0000000000 0 0000
0000 Venture Capital-Backed San Diego, CA 00 00.000 0000000000 0
00000000 000000000 Formerly VC-backed Boston, MA 00 00000 000000000 00000
0000000 000000 Venture Capital-Backed Barcelona, Spain 00 0000 000000000000 0000
You’re viewing 5 of 43 competitors. Get the full list »

Aquinnah Patents

  • 12

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Aquinnah Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3047404-A1 Compounds, compositions and methods of use Pending 23-Dec-2016 000000000
EP-3557998-A1 Compouns, compositions and methods of use Pending 23-Dec-2016 000000000
AU-2017382360-A1 Compounds, compositions and methods of use Pending 23-Dec-2016 000000000
EP-3557998-A4 Compouns, compositions and methods of use Pending 23-Dec-2016 0000000000 0
JP-2020503314-A Compounds, compositions, and methods of use Pending 23-Dec-2016 A61P25/16
To view Aquinnah’s complete patent history, request access »

Aquinnah Executive Team (7)

Name Title Board Seat Contact Info
Glenn Larsen Ph.D Co-Founder, President, Chief Executive Officer & Board Member
Benjamin Wolozin Ph.D Co-Founder, Board Member & Chief Scientific Officer
Manfred Weigele Ph.D Co-Founder & Scientific Advisor
Joshua Fox JD Board Member & Corporate Counsel
Joseph Vacca Ph.D Vice President , Medicinal Chemistry, Scientific Advisor & Board Member
You’re viewing 5 of 7 executive team members. Get the full list »

Aquinnah Board Members (7)

Name Representing Role Since
Benjamin Wolozin Ph.D Aquinnah Co-Founder, Board Member & Chief Scientific Officer 000 0000
Charles Kunsch Ph.D AbbVie Ventures Board Observer 000 0000
Daniel Geffken Self Chief Financial Officer & Board Member 000 0000
Joseph Vacca Ph.D Aquinnah Vice President , Medicinal Chemistry, Scientific Advisor & Board Member 000 0000
Joshua Fox JD Aquinnah Board Member & Corporate Counsel 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Aquinnah Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aquinnah Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Tau Consortium Government 000 0000 000000 0
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Pfizer Ventures Corporate Venture Capital Minority 000 0000 000000 0
Takeda Pharmaceutical Company Corporation Minority 000 0000 000000 0
National institutes of Neurological Disorders and Stroke Other 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial